CANCERS BRONCHIQUES NON A PETITES CELLULES NON METASTATIQUES NON RESECABLES |
|
|
Référence |
Traitement |
Stade |
N pts |
RO % |
Survie médiane |
Survie à 5 ans |
p |
|
Furuse, 1999 (1) |
I. Concomitant : CDDP-MMC-VDS 2cures + RT (56Gy J2) |
IIIA/B |
156 |
89 |
16,5 mo |
15,8 % |
0,04 |
|
II. Séquentiel : CDDP-MMC-VDS 2cures puis RT (56Gy) |
158 |
66 |
13,3 mo |
8,9 % |
|||
|
Komaki, 2002 (2) |
I. Concomitant : CDDP-VP16 + RT (69,6 Gy J1 bid) |
|
81 |
71 |
15,5 mo |
15,5% |
|
|
II. Séquentiel : 2 x CDDP-VBL puis RT (63 Gy J50) potentialisée par CDDP |
81 |
73 |
16,4 mo |
13 % |
|||
|
Zatloukal, 2004 (3) |
I. Concomitant : CDDP-VNR (4 cycles) + RT (60 Gy J4 cycle 2) |
IIIA/B |
52 |
80 |
16,6 mo |
|
0,023 |
|
II. Séquentiel : CDDP-VNR x 4 puis RT (60 Gy) |
50 |
47 |
12,9 mo |
|
|||
|
Fournel, 2005 (4) |
I. Concomitant : CDDP-VP16 + RT (66 Gy J1) puis 2x CDDP-VNR |
IIIA/B |
100 |
40 |
16,3 mo |
|
0,24 |
|
II. Séquentiel : CDDP-VNR x 3 puis RT 66 Gy |
101 |
50 |
14,5 mo |
|
|||
|
Belani, 2005 (5) |
I. Paclitaxel-CBDCA x 2 puis RT 63 Gy |
IIIA/B |
91 |
|
13,0 mo |
|
|
|
II. Paclitaxel-CBDCA x 2 puis RT 63 Gy avec paclitaxel-CBDCA hebdom. |
74 |
|
12,7 mo |
|
|||
|
III. RT 63 Gy avec paclitaxel-CBDCA hebdom. puis Paclitaxel-CBDCA x 2 |
92 |
|
16,3 mo |
|
|||
|
Huber, 2006 (6) |
paclitaxel + carbo (AUC 6) 2 x puis |
IIIA/B |
303 |
|
|
|
|
|
I. RT 60 Gy |
|
113 |
|
14,1 mo |
|
0,09 |
|
|
II. RT 60 Gy avec paclitaxel hebdomadaire (60 mg/m²) |
|
101 |
|
18,7 mo |
|
||
|
Belderbos, 2007 (7) |
I. Concomitant : RT 66 Gy (24x/32j) + CDDP 6mg/m²/j |
inopérable I/IIIB |
80 |
61 |
16,5 mo |
|
NS |
|
II. Séquentiel : CDDP (75) + gemcitabine 2 cycles puis : RT 66 Gy (24x/32j) |
78 |
70 |
16,2 mo |
|
Références
(1) Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17(9):2692.
(2) Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002; 53(3):548-557.
(3) Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46(1):87-98.
(4) Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23(25):5910-5917.
(5) Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005; 16(7):1069-1075.
(6) Huber RM, Flentje M, Schmidt M, Pollinger B, Gosse H, Willner J, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 2006 Sep 20;24(27):4397-404
(7) Belderbos J, Uitterhoeve L, Van ZN, Belderbos H, Rodrigus P, van d, V, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007 Jan;43(1):114-21.